ABSTRACT
BACKGROUND: The clinical significance of subcentimeter nodules identified on staging chest computed tomography (CT) for sarcoma remains unknown. Our goal was to evaluate the effect of initial pulmonary nodule size and number on survival rates in young, newly diagnosed sarcoma patients. METHODS: Medical records were reviewed for all patients ≤50 years of age with primary, high-grade bone or soft tissue sarcoma at our institution over a 10-year period. This population was divided into patients with no nodules (group 1); 1 nodule <5 mm (group 2);>1 nodule <5 mm (group 3); and ≥1 nodule ≥5 mm (group 4). Kaplan-Meier analyses with log rank tests were performed to compare overall and disease-free survival between these 4 groups, as well as between patients with unilateral and bilateral nodules. RESULTS: There were 74 patients in group 1 (59.2%), 26 in group 2 (21%), 11 in group 3 (9%), and 13 in group 4 (10%). Mean follow-up was 74 (range, 6 to 191 mo) months. Survival was only slightly worse with larger nodules but significantly worse with multiple nodules. In addition, patients with bilateral nodules had a significantly worse prognosis than those with multiple unilateral nodules. CONCLUSIONS: These data suggest that in young patients with high-grade sarcoma, the number and distribution of subcentimeter pulmonary nodules are an important prognostic factor, whereas nodule size may be less relevant.
Subject(s)
Bone Neoplasms/pathology , Lung Neoplasms/secondary , Lung/pathology , Neoplasm Staging/methods , Sarcoma/secondary , Soft Tissue Neoplasms/pathology , Adolescent , Adult , Bone Neoplasms/diagnostic imaging , Bone Neoplasms/mortality , Child , Child, Preschool , Disease-Free Survival , Female , Humans , Infant , Kaplan-Meier Estimate , Lung/diagnostic imaging , Lung Neoplasms/diagnostic imaging , Lung Neoplasms/mortality , Male , Middle Aged , Prognosis , Retrospective Studies , Sarcoma/diagnostic imaging , Sarcoma/mortality , Soft Tissue Neoplasms/diagnostic imaging , Soft Tissue Neoplasms/mortality , Tomography, X-Ray Computed , Young AdultABSTRACT
BACKGROUND: Refusal of therapy is ethically acceptable for competent adults. Practitioner opinions regarding refusal of therapy in pediatric cancer patients has not been widely studied. This is the largest survey of oncology practitioners assessing support for refusal of chemotherapy. PROCEDURE: Pediatric oncology nurses/physicians were asked: "As their provider I would support refusal of chemotherapy by a family," with the following options: "Never support refusal," "Always support refusal," or "Support for refusal would depend on cure rate, age, or both." Variables assessed were: age (0 to 7, 8 to 13, 14 to 17 y) and cure rate (0% to 33%, 34% to 66%, 67% to 100%). RESULTS: A total of 957 practitioners responded. Fifty-six percent, 31%, and 0.2%, respectively, stated their support of chemotherapy refusal depended on "age and cure rate," "cure rate alone," or "age alone." Two percent and 11% indicated they would "always" or "never" support refusal, respectively. For a "modest" or "good" cure rate, support for refusal was <20%, whereas for a "poor" cure rate, the majority would support a family's refusal (53% to 78% age dependent). Within each cure rate, respondents were more likely to support refusal for older patients (P<0.001). CONCLUSIONS: The majority of practitioners surveyed viewed parental refusal of chemotherapy for children with a moderate or good expected cure rate as unacceptable, but were more accepting of refusal with a poor prognosis, especially for teenagers.
